Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial
Rodríguez-Moran M, Guerrero-Romero F
Archives of medical research · 53 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Fundación IMSS
Según 1 financiador declarado.
Publicación
- Publicado
- 2014-05-13 · Arch Med Res · vol. 45 · número 5 · págs. 388–393
- Editorial
- Elsevier BV
- Citado
- 70 citas · más que el 98% de estudios similares · 7.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 39 trabajos
- Acceso
- De pago
- Áreas de investigación
- Magnesium in Health and Disease · Magnesium Alloys: Properties and Applications · Magnesium Oxide Properties and Applications
- Palabras clave
- magnesium supplementation, hypomagnesemia, magnesium chloride, insulin resistance, HOMA-IR, fasting blood glucose, triglycerides, blood pressure, metabolic profile
- MeSH
- humans, magnesium deficiency, obesity, body weight, magnesium chloride, treatment outcome, administration, oral, drug administration schedule, follow-up studies, double-blind method, dietary supplements, adult, middle aged, female, male, intention to treat analysis, metabolic syndrome
2 autores
- Martha Rodríguez‐Morán🇲🇽Mexican Social Security Institute
- Fernando Guerrero‐Romero🇲🇽Mexican Social Security Institute
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background and aims
We undertook this study to determine the efficacy of oral magnesium supplementation in the improvement of the metabolic profile and blood pressure in metabolically obese, normal-weight (MONW) individuals.
Methods
A total of 47 MONW individuals with hypomagnesemia were enrolled in clinical a randomized double-blind placebo-controlled trial. Individuals in the intervention group received 30 mL of MgCl2 5% solution (equivalent to 382 mg of magnesium) and individuals in the control group 30 mL of placebo solution, once daily during 4 months. In the absence of obesity or overweight, the presence of fasting glucose levels ≥100 mg/dL, HOMA-IR index ≥3, triglyceride levels ≥150 mg/dL and/or systolic and diastolic blood pressure ≥140 and 90 mmHg defined the presence of the MONW phenotype. Hypomagnesemia was defined by serum magnesium concentration ≤1.8 mg/dL.
Results
At basal conditions there were no significant differences between groups. At the end of follow-up, changes in the mean of systolic (-2.1 vs. 3.9% mmHg, p <0.05) and diastolic (-3.8 vs. 7.5% mmHg, p <0.05) blood pressures, HOMA-IR index (-46.5 vs. -5.4%, p <0.0001), fasting glucose (-12.3 vs. -1.8% mg/dL, p <0.05) and triglyceride levels (-47.4% vs. 10.1% mg/dL, p <0.0001) were significantly lower in the subjects who received MgCl2 compared with individuals in the control group.
Conclusions
Oral magnesium supplementation improves the metabolic profile and blood pressure of MONW individuals.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.